Welcome to our dedicated page for prog news (Ticker: prog), a resource for investors and traders seeking the latest updates and insights on prog stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect prog's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of prog's position in the market.
Progenity, Inc. (NASDAQ: PROG) has priced an underwritten public offering of 7,645,259 shares at $3.27 per share, aiming to raise approximately $25 million. Proceeds will support operations and further research in molecular testing and precision medicine. The offering is set to close on December 7, 2020. Additionally, Progenity announced a private offering of $75 million in 7.25% convertible senior notes, with a potential additional $15 million. This offering is independent of the common stock sale and is also expected to close on the same date.
Progenity Inc. (NASDAQ: PROG) has announced a public offering of $25 million in common stock, with an option for underwriters to purchase an additional $3.75 million. A separate private offering of $75 million in convertible senior notes due 2025 has also been initiated, with an option for an additional $15 million. The offerings are not contingent upon each other and depend on market conditions. Piper Sandler & Co. and Wells Fargo Securities are managing the stock offering.
Progenity, Inc. (NASDAQ: PROG) plans to offer $75 million in convertible senior notes due 2025 to qualified institutional buyers, with an option for an additional $15 million. The notes will mature on December 1, 2025, and may be converted into common stock after 30 days from issuance. Progenity aims to utilize proceeds for operations, R&D in molecular testing and precision medicine, and other corporate purposes. Athyrium Capital Management has expressed interest in acquiring up to $103.5 million in notes. Additionally, Progenity intends to offer $25 million in common stock, independent of the notes offering.
Progenity, Inc. (Nasdaq: PROG) announced clinical verification data for its Preecludia™ test, designed to rule out preeclampsia risk. The test exhibited an impressive 98.2% negative predictive value (NPV), making it a potential first-of-its-kind tool for triaging pregnant women. Preeclampsia poses significant risks to maternal and fetal health, with a U.S. market potential of up to $3 billion. The company plans to commercialize the test in 2021 following further validation studies, highlighting the urgent need for improved diagnostic tools in women's health.
Progenity, Inc. (Nasdaq: PROG) will present at the San Antonio Breast Cancer Virtual Symposium (SABCS) from December 8-11, 2020. The presentation is titled Describing the cancer spectrum in families with CHEK2 pathogenic and likely pathogenic variants by mutation type, authored by Julia G Moroney and Michele S. Basiliere. It is scheduled for December 9, 2020, at 8:00 AM CT, with poster number PS8-18. Abstracts will be published in late November 2020, and the poster will be available on the Progenity website after the conference.
Progenity, Inc. (Nasdaq: PROG) announced that CEO and co-founder Harry Stylli, Ph.D., will participate in a fireside chat at the Piper Sandler Healthcare Conference from December 1-3, 2020. The pre-recorded chat will be accessible starting November 23, 2020, on the company's website, where it will remain available through December 3. Progenity specializes in developing and commercializing molecular testing products aimed at improving healthcare outcomes through precision medicine and multi-omics approaches.
Progenity (Nasdaq: PROG) announced a Preeclampsia Virtual R&D Day set for November 20, 2020, from 11 a.m. to 1 p.m. ET. The event will feature senior management and guest speakers discussing the clinical development of the Preecludia™ rule-out test for preeclampsia. Topics will include the pathophysiology of preeclampsia and its economic burden. Attendees can join via a live audio webcast on Progenity’s investor website. A replay will be available afterwards.
Progenity specializes in developing molecular testing products aimed at improving healthcare through precise diagnostics.
Progenity (Nasdaq: PROG) announced a 12% increase in test volumes, totaling 84,067 in Q3 2020. Revenue rose to $25.9 million from $17.3 million in Q2, with a notable improvement in gross margin from -26.5% to 9.2%. The company secured a $15.7 million tax refund under the CARES Act and achieved a key milestone for its preeclampsia test, transferring it to operations for validation in 2021. Despite these gains, the net loss was $47.1 million. Progenity enhances its COVID-19 testing capacity to meet increased demand ahead of winter.
Progenity (Nasdaq: PROG) announced promising preliminary preclinical data for its oral drug delivery system (DDS), aimed at improving treatment for ulcerative colitis. The study, using a canine model, showed that the DDS effectively localized drug delivery to the large intestine with no adverse effects. Both drug-device candidates, PGN-001 and PGN-600, demonstrated successful pharmacokinetic results, suggesting enhanced efficacy and patient safety. Progenity plans to test the DDS in human volunteers in Q1 2021.
Progenity, Inc. (NASDAQ: PROG) will report its third quarter 2020 financial results on November 9, 2020, after market close. The event will include a conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. Investors can access the call by dialing specified numbers or through a live webcast on the company's website. Progenity specializes in molecular testing products and aims to improve healthcare precision through its innovative diagnostic solutions.
FAQ
What is the market cap of prog (prog)?
